BRAF and metastatic melanoma: More recently, combined BRAF and MEK inhibition out-performed BRAF inhibitors monotherapy in three randomized Phase 3 trials [5-9] and the combinations of dabrafenib plus trametinib and vemurafenib plus cobimetinib are now approved by the FDA and EMA for the treatment of metastatic melanoma with a BRAF V600E or V600K mutation.